Tabula Rasa HealthCare (NASDAQ:TRHC) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday, September 15th.
Several other equities research analysts also recently weighed in on the stock. Stifel Nicolaus started coverage on shares of Tabula Rasa HealthCare in a research note on Tuesday, September 11th. They issued a “hold” rating and a $95.00 price target for the company. Cantor Fitzgerald started coverage on shares of Tabula Rasa HealthCare in a research report on Thursday, September 6th. They set an “overweight” rating and a $99.00 target price for the company. Oppenheimer boosted their target price on shares of Tabula Rasa HealthCare from $65.00 to $86.00 and gave the stock an “outperform” rating in a research report on Thursday, August 23rd. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, Citigroup boosted their target price on shares of Tabula Rasa HealthCare from $57.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Tabula Rasa HealthCare has an average rating of “Buy” and an average price target of $69.75.
TRHC stock traded down $3.07 during midday trading on Friday, hitting $72.47. The stock had a trading volume of 426,800 shares, compared to its average volume of 348,667. Tabula Rasa HealthCare has a 1-year low of $24.24 and a 1-year high of $91.16. The company has a quick ratio of 0.33, a current ratio of 0.36 and a debt-to-equity ratio of 0.11. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -1,858.50, a PEG ratio of 6.13 and a beta of 2.85.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.12. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. The firm had revenue of $48.60 million during the quarter, compared to the consensus estimate of $46.73 million. Research analysts expect that Tabula Rasa HealthCare will post 0.53 earnings per share for the current year.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $85.98, for a total value of $687,840.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 40,000 shares of company stock worth $2,928,240. Corporate insiders own 14.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in TRHC. BlackRock Inc. increased its holdings in Tabula Rasa HealthCare by 29.7% during the 2nd quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock worth $135,288,000 after acquiring an additional 484,979 shares during the period. Jennison Associates LLC increased its holdings in Tabula Rasa HealthCare by 29.5% during the 2nd quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock worth $48,373,000 after acquiring an additional 172,693 shares during the period. NN Investment Partners Holdings N.V. bought a new stake in Tabula Rasa HealthCare during the 2nd quarter worth approximately $29,439,000. Braun Stacey Associates Inc. increased its holdings in Tabula Rasa HealthCare by 199.0% during the 2nd quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock worth $19,219,000 after acquiring an additional 200,394 shares during the period. Finally, Northern Trust Corp increased its holdings in Tabula Rasa HealthCare by 52.3% during the 2nd quarter. Northern Trust Corp now owns 227,503 shares of the company’s stock worth $14,522,000 after acquiring an additional 78,112 shares during the period. Institutional investors own 75.15% of the company’s stock.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Featured Article: What Factors Can Affect Return on Equity?
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.